Drug Profile


Alternative Names: STY 2108; WEB 2170

Latest Information Update: 14 Aug 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Azepines; Small molecules; Triazoles
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Ischaemic heart disorders; Transplant rejection

Most Recent Events

  • 14 Aug 1997 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
  • 07 Apr 1995 Discontinued-Preclinical for Transplant rejection in United Kingdom (Unknown route)
  • 06 Jan 1995 Preclinical development for Transplant rejection in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top